Clinical research · Philippines
Run your trial in the Philippines — with someone who has already run one.
I match global sponsors to vetted Philippine CROs, then stay on as your local advisor through execution. You get the shortlist, the negotiated terms, and a straight answer about whether the country fits your protocol at all.
No obligation · Thirty minutes is enough to get a candid read
30–50%
Lower per-patient cost
Same protocol, materially smaller site budget
Phase I–IV
Plus non-interventional
Feasibility through closeout
No fee to you
Paid by the partner CRO
You know my incentive before you weigh my advice
A 30–50% reduction in per-patient cost, without cutting quality corners. Range reflects therapeutic area and site mix.
The case for the Philippines
Cost, scale, English fluency, and a regulatory pathway that is actually navigable.
Four conditions rarely hold at once. Where they do, sponsors move trial volume — and Southeast Asia is where they have been moving it.
30–50%Cost reduction
Lower per-patient cost
Run the same protocol against a materially smaller site budget. The saving comes from local cost structure, not from thinner monitoring or reduced source verification.
100M+Population
English-speaking, largely treatment-naïve
Consent documents and case report forms need no translation layer. A treatment-naïve pool means cleaner signal and fewer washout exclusions at screening.
ICH-GCPStandard
Trained investigators, accredited sites
GCP-certified principal investigators at facilities that global sponsors already contract with. This is the question your QA group will ask first, so it is the one I document first.
PH FDARegulator
A defined submission route
Philippine FDA and ethics committee review follow a published sequence. Knowing where it stalls — and who to call when it does — is most of the value of a local advisor.
Engagement sequence
Three steps, in order. You skip the RFP cycle.
I handle vendor scouting, screening, and negotiation, so you land with the right partner the first time instead of the third.
You tell me the study
Therapeutic area, phase, target enrollment, budget envelope, and your timeline constraints. Thirty minutes is usually enough.
Output — a candid read on whether the Philippines fitsI shortlist and negotiate
I run competitive proposals across vetted Philippine CROs and negotiate pricing and timelines on your behalf. You see the comparison, including the partners I ruled out and why.
Output — a costed shortlist with negotiated termsYou sign; I stay on
You contract directly with the CRO. I remain engaged as your local advisor through startup and execution — the person who reads the room when a site goes quiet.
Output — ongoing local representation
Professional record
I know both sides of the table: sponsor economics and local execution.
As a Clinical Lead at a Philippine CRO, I manage studies from feasibility through closeout. At BPIQ & BiopharmIQ, a U.S.-based biopharma intelligence company, I analyse clinical catalysts, regulatory milestones, financings, and M&A.
That combination is the point. Sponsor strategy set without local execution reality produces timelines nobody can hit; local execution without sponsor economics produces a partner who cannot read your board deck.
- Study operations
- Phase I–IV and non-interventional, feasibility through closeout
- Quality systems
- ICH-GCP-aligned SOPs and quality management
- Regulatory
- Submissions, site management, sponsor communications
- Market intelligence
- Clinical catalysts, competitive and M&A analysis
Next step
Planning a trial in Asia? Start with thirty minutes.
Tell me a little about the study — therapeutic area and phase is enough. You will get a realistic view of cost, timeline, and the partners worth talking to, including the case against.